Dissolution variability unexplained during IND/NDA filing – CMC risk assessment and mitigation







Published on 22/04/2026

Addressing Unexplained Dissolution Variability During IND/NDA Filing: A Comprehensive Playbook

Dissolution variability during the Investigational New Drug (IND) and New Drug Application (NDA) filing can lead to significant delays, regulatory scrutiny, and increased costs. This variability can undermine the confidence in the quality and efficacy of a pharmaceutical product, posing challenges in both development and commercialization phases. After reading this article, pharmaceutical professionals will gain actionable insights into diagnosing, addressing, and documenting dissolution challenges effectively, ensuring compliance with FDA, EMA, and ICH guidelines.

This playbook adopts a structured approach to tackle dissolution variability, guiding professionals across various roles—including Production, Quality Control (QC), Quality Assurance (QA), Engineering, and Regulatory Affairs (RA)—in implementing quick triage actions, deep-dive analyses, effective controls, and maintaining inspection readiness.

Symptoms/Signals on the Floor or in the Lab

Identifying symptoms of dissolution variability is the first step in managing potential CMC risks. Symptoms

may manifest as:

  • Inconsistency in Dissolution Profiles: Observable deviations in dissolution rates, especially when batch results differ significantly from established baselines.
  • High Variability in Batch Results: Statistical measures such as standard deviations exceed acceptable limits outlined in the regulatory filings.
  • Out-of-Specification (OOS) Results: Reports of OOS results during stability studies affecting the product’s shelf life and marketability.
  • Trending Issues: An unexpected rise in variations seen across batches or during different stages of the development process.

Recognizing these symptoms promptly allows teams to implement immediate containment measures effectively.

Likely Causes

Understanding the root causes of dissolution variability can aid in the effective design of corrective actions. The categories below provide a framework for investigating potential factors:

Pharma Tip:  QbD elements missing during regulatory review – how to redesign formulation strategy
Category Likely Causes
Materials Inconsistent raw material characteristics, active pharmaceutical ingredient (API) polymorphism, excipient variability.
Method Improper dissolution testing protocols, inadequate solubilization techniques, variations in test setups.
Machine Inadequate calibration of dissolution apparatus, wear and tear of equipment components.
Man Operator variability suggesting poor training or inadequate SOP adherence.
Measurement Inconsistent sampling times, improper analytical methods leading to biased data.
Environment Fluctuations in temperature/humidity affecting product stability during testing.

Immediate Containment Actions (first 60 minutes)

Once symptoms of dissolution variability are identified, immediate containment actions must be undertaken:

  • Stop Production: Cease any ongoing operations involving the affected batches to prevent further variability.
  • Isolate Affected Batches: Segregate batches flagged for variability and place them on hold for evaluations.
  • Review Dissolution Testing Protocols: Ensure testing methods align with established SOPs and regulatory guidelines.
  • Notify Relevant Teams: Inform Production, QA, QC, Engineering, and RA teams about the variability issue for coordinated investigation efforts.
  • Initiate Documentation: Begin detailed records of findings, observations, and actions taken to maintain an audit trail.

Investigation Workflow

A thorough and systematic investigation is critical to diagnosing the source of dissolution variability. Follow this workflow:

  1. Data Collection:
    • Collect batch records, raw material certificates of analysis (CoA), and dissolution test results.
    • Review historical data for trends in dissolution results—both successful and problematic.
  2. Data Analysis:
    • Utilize statistical tools to analyze variance and identify patterns in OOS results.
    • Overlay product specifications with current test results to pinpoint discrepancies.
  3. Interdisciplinary Review:
    • Engage cross-functional teams to obtain diverse insights on potential issues.
    • Facilitate brainstorming sessions to ensure no factors are overlooked.
  4. Documentation:
    • Maintain a log of findings and actions, including responsibility assignments.
    • Ensure all documentation is accessible, accurate, and compliant with regulatory standards.

Root Cause Tools

Selecting the right tool for root cause analysis is vital. Here’s a guide to the most effective methodologies:

  • 5-Why Analysis: Best used for straightforward issues. This method encourages asking “Why?” iteratively to uncover underlying causes. Ideal for tracing back to basic root causes in dissolution variability.
  • Fishbone Diagram: Suitable for complex issues involving multiple potential causes. This diagram allows teams to categorize causes into groups like Materials, Method, Machine, Man, Measurement, and Environment.
  • Fault Tree Analysis: Effective for analyzing system failures systematically. It aids in visualizing the pathways that lead to dissolution failures, facilitating understanding of various failure modes and their interactions.
Pharma Tip:  Formulation Instability Problems? Development Solutions for Robust Products

CAPA Strategy

Implementing a robust Corrective and Preventive Action (CAPA) strategy involves:

  1. Correction: Immediate actions to manage and correct the specific dissolution deviations, including re-testing batches with modified procedures.
  2. Corrective Action: Long-term actions designed to eliminate root causes, which may involve supplier changes, equipment updates, or refining analytical methodologies.
  3. Preventive Action: Developing a detailed risk management plan that includes ongoing monitoring strategies, staff training, and regular equipment maintenance.

Control Strategy & Monitoring

Once corrective measures are implemented, establishing a control strategy is critical to preventing future variability:

  • Statistical Process Control (SPC): Utilize SPC to monitor dissolution testing over time, ensuring that the process remains in control.
  • Trending Analysis: Regularly review trends in dissolution data to detect early signs of variability, enabling proactive intervention.
  • Alarm Systems: Implement alarm thresholds for deviation triggers to enable immediate action when variability is detected.
  • Verification Procedures: Establish verification steps to validate that CAPA measures have been effective before resuming normal operations.

Validation / Re-qualification / Change Control Impact

Regulatory compliance necessitates that any changes resulting from investigations or CAPAs undergo validation, re-qualification, and/or change control processes:

Related Reads

  • Validation: Re-validate analytical methods if modifications affect dissolution testing.
  • Re-qualification: If equipment changes are involved, ensure re-qualification processes are followed to maintain compliance.
  • Change Control: Maintain rigorous change control documentation regarding any alterations in formulation, process, or equipment to comply with regulatory expectations.

Inspection Readiness: What Evidence to Show

Being prepared for regulatory inspections is crucial. Here’s what documentation to prepare:

  • Records: Ensure batch records, dissolution logbooks, and CAPA documentation are complete, up-to-date, and easily accessible.
  • Logs: Maintain detailed logs of all testing and investigation activities, including deviations and resolutions.
  • Batch Documentation: Provide comprehensive batch documentation that outlines production conditions, testing methods, and results.
  • Deviations: Document any deviations meticulously, including root cause analysis, CAPA measures undertaken, and evidence of results.
Pharma Tip:  Formulation fails stability targets during scale-up preparation – CMC risk assessment and mitigation

FAQs

What are common causes of dissolution variability?

Common causes include inconsistent raw materials, improper testing methods, machine calibration issues, and environmental factors.

How can I quickly identify symptoms of dissolution variability?

Look for OOS results, statistical inconsistencies, and trending data that indicate variability across batches.

What does CAPA entail in the context of dissolution issues?

CAPA involves correction of ongoing issues, corrective actions to eliminate root causes, and preventive actions to mitigate future risks.

How should I document investigations into dissolution variability?

Document findings, action steps, data collected, and team reviews in accessible records to ensure compliance and audit readiness.

What monitoring strategies can help prevent dissolution variability?

Implement SPC, trending analysis, alarm systems, and verification procedures to monitor sustainability in the dissolution process.

When should a change control process be initiated?

A change control process should be initiated when modifications to materials, methods, or equipment occur that could impact dissolution testing.

What tools are best for root cause analysis of dissolution variability?

Effective tools include 5-Why analysis for straightforward issues, Fishbone diagrams for complex factors, and Fault Tree analysis for system failures.

What should my validation process include after changes?

The validation process should re-assess methods affected by changes, validate system performance after interventions, and ensure compliance with regulatory standards.

How can statistical process control (SPC) aid in managing dissolution variability?

SPC monitors process consistency through statistical techniques, allowing for early detection of variations and enabling timely corrective actions.